As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Announcing the launch of In Review
In-Review
Journal of Ovarian Research, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
New reviewer recruitment
The Journal of Ovarian Research invites you to join our team of reviewers in assessing manuscripts. For consideration, please send your CV to dana.dovey@biomedcentral.com.
Articles
-
-
A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy
-
A combination of spearmint and flaxseed extract improved endocrine and histomorphology of ovary in experimental PCOS
-
MiR-29c-3p, a target miRNA of LINC01296, accelerates tumor malignancy: therapeutic potential of a LINC01296/miR-29c-3p axis in ovarian cancer
-
Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer
-
Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
-
MicroRNAs in ovarian function and disorders
-
Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis
-
Developmental potential of human oocytes matured in vitro followed by vitrification and activation
-
High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer
Featured article
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer
Ovarian cancer is the leading cause of gynecologic cancer death in the United States despite effective first-line systemic chemotherapy. Cancer stem cells (CSCs) retain the ability to self-renew and proliferate and may be a means of harboring disease that evades standard treatment strategies. We previously performed a high-throughput screen to assess differential protein expression in ovarian CSCs compared to non-CSCs and observed that Thy-1 was more highly expressed in CSCs. Our primary aim was to validate Thy-1 (CD90) as a cancer stem cell (CSC) marker in epithelial ovarian cancer (EOC), correlate with clinical outcomes, and assess as a potential therapeutic target.
Aims and scope
Journal of Ovarian Research is an open access, peer reviewed, online journal that aims to provide a forum for high-quality basic and clinical research on ovarian function, abnormalities, and cancer. The journal focuses on research that provides new insights into ovarian functions as well as prevention and treatment of diseases afflicting the organ.
Topical areas include, but are not restricted to:
- Ovary development, hormone secretion and regulation
- Follicle growth and ovulation
- Infertility and Polycystic ovarian syndrome
- Regulation of pituitary and other biological functions by ovarian hormones
- Ovarian cancer, its prevention, diagnosis and treatment
- Drug development and screening
- Role of stem cells in ovary development and function
Journal of Ovarian Research is affiliated with the CROWN initiative, Core Outcomes in Women’s Health. CROWN is an international initiative, led by journal editors, to harmonise outcome reporting in women’s health research. We are coming together to address the widespread, unwarranted variation in reporting of outcomes. CROWN’s main aim is to encourage researchers to report core outcome sets for key conditions in women’s health.
Editors-in-Chief
Sham S Kakar, University of Louisville, USA
Benjamin K Tsang, University of Ottawa, Canada
Advertisement
Annual Journal Metrics
-
Speed
68 days to first decision for reviewed manuscripts only
54 days to first decision for all manuscripts
123 days from submission to acceptance
14 days from acceptance to publication
Citation Impact
2.469 - 2-year Impact Factor
2.717 - 5-year Impact Factor
0.936 - Source Normalized Impact per Paper (SNIP)
0.938 - SCImago Journal Rank (SJR)
Usage
352,997 Downloads
196 Altmetric mentions
Advertisement
